BURGWEDEL, Germany/PRNewswire/ -- MYR Pharma today announced that the results of 48 weeks of administration of Myrcludex, MYR`s first-in-class entry inhibitor for treatment of hepatitis B and D infection, will be presented at the Presidential Plenary Session of the upcoming AASLD meeting in San Francisco:
- Heiner Wedemeyer, "Interim results of a multicenter, open-label Phase 2 clinical trial (MYR203) to assess safety and efficacy of Myrcludex B in combination with PEG-interferon alpha 2 a in patients with chronic HBV/HDV co-infection", Presidential Plenary Session (Clinical Science), November 12, 8:45 am.
"I am looking forward to share the encouraging results of this study at this very important meeting", said Heiner Wedemeyer, MD, Professor at Essen University Medical School and Chairman of MYR`s Clinical Advisory Board.
About Myrcludex
Myrcludex is a first-in-class entry inhibitor for treatment of chronic hepatitis B and D infections. The drug inhibits the HBV receptor on the hepatocyte surface and prevents the infection of healthy cells and viral spreading within the liver. Myrcludex has received Orphan Designation for treatment of HDV infection from EMA and FDA, PRIME scheme eligibility from EMA, and a breakthrough therapy designation from FDA.
Media Contact: Alexey Eliseev, 1-617-953-0767
